Reports Q3 revenue $8.09B, consensus $7.95B. “We’re building momentum, with another quarter of solid execution on our commitments. We continue to deliver durable revenue growth, with particular strength in multiple businesses, as well as in international markets as we expand access to our innovative healthcare technologies around the globe,” said Geoff Martha, Medtronic chairman and chief executive officer. “Our recent major product approvals – including transformative products in the diabetes, cardiac rhythm management, neuromodulation, hypertension, and pulsed field ablation spaces – increase our confidence in driving reliable growth over the coming quarters and years.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MDT:
- Intuitive Surgical price target raised to $385 from $335 at Evercore ISI
- Medtronic price target raised to $92 from $82 at RBC Capital
- Medtronic put volume heavy and directionally bearish
- Medtronic announces FDA approval of Percept RC DBS system
- Orchestra BioMed announces initiation of BACKBEAT study of AVIM therapy